MDR-TB RESOURCES - WHO

 

The Global TB Programme, World Health Organization

Mission
The WHO Global TB Programme aims to advance universal access to TB prevention, care and control, guide the global response to threats, and promote innovation.

Core functions

  • Provide global leadership on matters critical to TB;

  • Develop evidence-based policies, strategies and standards  or TB prevention, care and control, and monitor their implementation;

  • Jointly with WHO regional and country offices, provide technical support to Member States, catalyze change, and build sustainable capacity;

  • Monitor the global TB situation, and measure progress in TB care, control, and financing;

  • Shape the TB research agenda and stimulate the generation, translation and dissemination of valuable knowledge;

  • Facilitate and engage in partnerships for TB action.

 For more information and resources on Drug-Resistant TB of the Global TB Programme, please visit: http://www.who.int/tb/challenges/mdr/en/index.html

GUIDELINES AND TOOLS

2013                                                         2012                                                               2011

GLOBAL REPORT

 

 

FACTSHEETS

 

 

OTHER RESOURCES

 

 

PEER-REVIEWED PUBLICATIONS

  1. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione MC. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. Lancet Infect Dis. 2013 Aug;13(8):690-7. doi:10.1016/S1473-3099(13)70130-0. Epub 2013 Jun 4. PubMed PMID: 23743044. (Full text)
     
  2. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, Hollm-Delgado MG, Keshavjee S, DeRiemer K, Centis R, D'Ambrosio L, Lange CG, Bauer M, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J. 2013 Jul;42(1):156-68. doi:10.1183/09031936.00134712. Epub 2012 Oct 25. PubMed PMID: 23100499. (Abstract)
     
  3. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D'Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013 Jul;42(1):169-79. doi:10.1183/09031936.00136312. Epub 2012 Oct 11. PubMed PMID: 23060633. (Abstract)
     
  4. Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis [Review article]. Int J Tuberc Lung Dis. 2013 Oct;17(10):1257-66. doi: 10.5588/ijtld.12.0863. Epub 2013 Jun 3. (Abstract)
     
  5. Falzon D, Weyer K, Raviglione MC. Drug-resistant tuberculosis: latest advances. The Lancet Respiratory Medicine, Volume 1, Issue 1, Pages e9 - e10, March 2013. doi:10.1016/S2213-2600(12)70056-5 (Full text).
     
  6. Harding R, Foley KM, Connor SR, Jaramillo E. Palliative and end-of-life care in the global response to multidrug-resistant tuberculosis. Lancet Infect Dis. 2012 Aug;12(8):643-6. doi: 10.1016/S1473-3099(12)70084-1. Epub 2012 Jun 11. PubMed PMID: 22691837. (Full text)
     
  7. Connor S, Foley K, Harding R, Jaramillo E. Declaration on palliative care and MDR/XDR-TB. Int J Tuberc Lung Dis. 2012 Jun;16(6):712-3. doi:10.5588/ijtld.12.0267. PubMed PMID: 22613682. (Full text)
     
  8. Coleman CH, Selgelid MJ, Reis A, Reichman LB, Jaramillo E. The role of informed consent in tuberculosis testing and screening. Eur Respir J. 2012 May;39(5):1057-9. doi: 10.1183/09031936.00211611. PMID: 22547729. (Full text)
     
  9. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ. 2012 Feb 1;90(2):111-119D. doi: 10.2471/BLT.11.092585. Epub 2011 Nov 7. PubMed PMID: 22423162; PubMed Central PMCID: PMC3302554. (Full text)
     
  10. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, Weil D, Raviglione M. MDR tuberculosis--critical steps for prevention and control. N Engl J Med. 2010 Sep 9;363(11):1050-8. doi: 10.1056/NEJMra0908076. PubMed PMID:20825317. (Full text)
     
  11. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M; Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009 May 30;373(9678):1861-73. doi:10.1016/S0140-6736(09)60331-7. Epub 2009 Apr 15. Review. PubMed PMID: 19375159. (Full text)
     
  12. Raviglione MC. Facing extensively drug-resistant tuberculosis--a hope and a challenge. N Engl J Med. 2008 Aug 7;359(6):636-8. doi: 10.1056/NEJMe0804906. PubMed PMID: 18687645. (Full text)
     
  13. Raviglione MC, Smith IM. XDR tuberculosis--implications for global public health. N Engl J Med. 2007 Feb 15;356(7):656-9. PubMed PMID: 17301295. (Full text)
     
  14. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione M; WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006 Dec 16;368(9553):2142-54. PubMed PMID: 17174706. (Full text)
     
  15. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001 Apr 26;344(17):1294-303. PubMed PMID: 11320389. (Full text)
     

   16.     Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for             antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-        Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998 Jun 4;338(23):1641-9. Erratum in: N England J Med 1998 Jul 9;339(2):139. PubMed PMID:9614254. (Full text)